AU2018201889A1 — Topical formulation for a jak inhibitor
Assigned to Incyte Holdings Corp · Expires 2018-04-12 · 8y expired
What this patent protects
This invention relates to pharmaceutical formulations for topical skin application comprising (R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1 yl]propanenitrile, or a pharmaceutically acceptable salt thereof, and use in the treatment of skin disorders. PARABE…
USPTO Abstract
This invention relates to pharmaceutical formulations for topical skin application comprising (R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1 yl]propanenitrile, or a pharmaceutically acceptable salt thereof, and use in the treatment of skin disorders. PARABEN PHASE PropyleneGyo AQUEOUS PHASE Methyl Paraben - Mix NF Purified Water Propyl Paraben NF 4mix 4Edetate Disodium Polyethylene Glycol USP Mix ACTIVE PHASE XANTHAN GUM PHASE Propylene Glycol Light Mieral Oil WgUSP Glyceryl StearateX Polysorbate 20 NF Mx/Heat White Petrolatum i ___.:::Mix Cetyl Alcohol NF Emulsify Stearyl Alcohol NF Peoytao Dimethicone 360 t t Mix /Cool Medium Chainj Triglycerides In Process Test Content Uniformity Topical formulation SFill in Tubes
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.